TY - JOUR
T1 - Predictors of Systolic Heart Failure and Mortality Following Orthotopic Liver Transplantation
T2 - a Single-Center Cohort
AU - Sakr, Antoine E.
AU - Fraser, Gary E.
AU - Doctorian, Tanya P.
AU - Kim, Hyungjin B.
AU - Narasimha, Deepika
AU - Abudayyeh, I.
AU - Hilliard, Anthony D.
AU - Shih, W.
AU - de Vera, Michael E.
AU - Baron, Pedro W.
AU - Volk, Michael L.
AU - Stoletniy, Liset N.
N1 - Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/7/1
Y1 - 2019/7/1
N2 - Objectives: The purpose of this study was to identify risk factors that may predict heart failure with reduced ejection fraction (HFrEF) following orthotopic liver transplantation (OLT) and associated mortality. Background: HFrEF following OLT is a poorly understood phenomenon, reported in 3% to 7% of transplanted patients. Methods: This is a retrospective analysis of 176 consecutive patients who underwent OLT from 2010 to 2017. Multivariate logistic regression was used to identify associations between cardiovascular risk factors and perioperative variables with post-OLT HFrEF, defined as reduction in left ventricular ejection fraction of at least 10% and left ventricular ejection fraction less than or equal to 40% with acute heart failure symptoms. Multivariate cox proportional hazards regression (with inverse probability weighting by propensity scores) was used to evaluate effects of HFrEF on 1-year mortality. Results: Of the176 patients, 14% developed HFrEF with a median of 5 days. History of heart failure (OR 10.99, 2.15–56.09; P = .04) and intraoperative transfusion of greater than 11 units of packed red blood cells (OR 3.377, 1.025–11.13; P = .045) were associated with increased incidence of HFrEF. Pre-transplant hemoglobin greater than 8.5 g/dL (OR 0.252, CI 0.0954- 0.665; P = .05) was protective against HFrEF. Thirty-three percent of HFrEF group died within 1 year (HR 7.36, 2.57–21.12; P < .001). Conclusions: The incidence of acute HFrEF post-OLT is 14% and is associated with a 7-fold increase in 1-year mortality. Cirrhotic cardiomyopathy and stress-induced cardiomyopathy maybe the underlying mechanisms. Our study identified risk factors associated with post-OLT HFrEF and should provide additional guidance for risk stratification of patients undergoing OLT.
AB - Objectives: The purpose of this study was to identify risk factors that may predict heart failure with reduced ejection fraction (HFrEF) following orthotopic liver transplantation (OLT) and associated mortality. Background: HFrEF following OLT is a poorly understood phenomenon, reported in 3% to 7% of transplanted patients. Methods: This is a retrospective analysis of 176 consecutive patients who underwent OLT from 2010 to 2017. Multivariate logistic regression was used to identify associations between cardiovascular risk factors and perioperative variables with post-OLT HFrEF, defined as reduction in left ventricular ejection fraction of at least 10% and left ventricular ejection fraction less than or equal to 40% with acute heart failure symptoms. Multivariate cox proportional hazards regression (with inverse probability weighting by propensity scores) was used to evaluate effects of HFrEF on 1-year mortality. Results: Of the176 patients, 14% developed HFrEF with a median of 5 days. History of heart failure (OR 10.99, 2.15–56.09; P = .04) and intraoperative transfusion of greater than 11 units of packed red blood cells (OR 3.377, 1.025–11.13; P = .045) were associated with increased incidence of HFrEF. Pre-transplant hemoglobin greater than 8.5 g/dL (OR 0.252, CI 0.0954- 0.665; P = .05) was protective against HFrEF. Thirty-three percent of HFrEF group died within 1 year (HR 7.36, 2.57–21.12; P < .001). Conclusions: The incidence of acute HFrEF post-OLT is 14% and is associated with a 7-fold increase in 1-year mortality. Cirrhotic cardiomyopathy and stress-induced cardiomyopathy maybe the underlying mechanisms. Our study identified risk factors associated with post-OLT HFrEF and should provide additional guidance for risk stratification of patients undergoing OLT.
UR - http://www.scopus.com/inward/record.url?scp=85068545356&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068545356&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2019.04.063
DO - 10.1016/j.transproceed.2019.04.063
M3 - Article
C2 - 31303409
SN - 0041-1345
VL - 51
SP - 1950
EP - 1955
JO - Transplantation Proceedings
JF - Transplantation Proceedings
IS - 6
ER -